HomeCompareRAFA vs PLD

RAFA vs PLD: Dividend Comparison 2026

RAFA yields 3030.30% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RAFA wins by $500360607180.90M in total portfolio value
10 years
RAFA
RAFA
● Live price
3030.30%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$500360607186.81M
Annual income
$469,859,227,990,298,900.00
Full RAFA calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — RAFA vs PLD

📍 RAFA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRAFAPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RAFA + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RAFA pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RAFA
Annual income on $10K today (after 15% tax)
$257,575.76/yr
After 10yr DRIP, annual income (after tax)
$399,380,343,791,754,050.00/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, RAFA beats the other by $399,380,343,787,715,900.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RAFA + PLD for your $10,000?

RAFA: 50%PLD: 50%
100% PLD50/50100% RAFA
Portfolio after 10yr
$250180303596.36M
Annual income
$234,929,613,997,524,800.00/yr
Blended yield
93.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

RAFA
No analyst data
Altman Z
3.1
Piotroski
4/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RAFA buys
0
PLD buys
0
No recent congressional trades found for RAFA or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRAFAPLD
Forward yield3030.30%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$500360607186.81M$5.91M
Annual income after 10y$469,859,227,990,298,900.00$4,750,725.19
Total dividends collected$498252908594.85M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: RAFA vs PLD ($10,000, DRIP)

YearRAFA PortfolioRAFA Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$313,730$303,030.30$11,241$540.96+$302.5KRAFA
2$9,220,718$8,885,026.99$13,019$991.13+$9.21MRAFA
3$253,918,671$244,052,501.99$15,801$1,870.97+$253.90MRAFA
4$6,552,701,214$6,281,008,236.19$20,609$3,701.21+$6552.68MRAFA
5$158,496,977,633$151,485,587,333.73$29,919$7,867.97+$158496.95MRAFA
6$3,594,020,691,580$3,424,428,925,512.90$50,631$18,617.74+$3594020.64MRAFA
7$76,416,745,778,469$72,571,143,638,478.27$105,528$51,352.20+$76416745.67MRAFA
8$1,523,841,939,473,922$1,442,076,021,490,960.80$287,364$174,449.42+$1523841939.19MRAFA
9$28,505,961,865,899,772$26,875,450,990,662,680.00$1,081,760$774,280.77+$28505961864.82MRAFA
10$500,360,607,186,811,600$469,859,227,990,298,900.00$5,908,209$4,750,725.19+$500360607180.90MRAFA

RAFA vs PLD: Complete Analysis 2026

RAFAStock

Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.

Full RAFA Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this RAFA vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RAFA vs SCHDRAFA vs JEPIRAFA vs ORAFA vs KORAFA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.